Last 24 hoursStory cluster

Regenxbio's Gene Therapy Faces Side Effects Amid FDA Approval

2 sources · 0 editorials3 factsMay 13 – May 14, 2026

Source coverage

Original publisher articles in this cluster. Broadside has not yet written editorial coverage.

With new data, Regenxbio to seek FDA approval of Duchenne gene therapy

via BioPharma Dive1 day ago

Regenxbio hits Duchenne gene therapy milestone, eyes 2027 FDA approval

via endpoints.news1 day ago

← Back to home